Novel Oncolytic Virus-Based Platform Technology to Transform the Detection and Treatment of Cancer
Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company focused on the development of a proprietary oncolytic vaccinia virus platform for the safe and effective diagnosis and treatment of cancer.
The company’s lead investigational product candidate, GL-ONC1, is a highly-selective, attenuated (Lister strain) vaccinia virus incorporating bioluminescent technology, and is designed to locate, enter and destroy tumors and metastases without harming healthy cells in the body. GL-ONC1 is being studied in Phase I/II human clinical trials.
Beyond GL-ONC1, the company’s significant depth of experience in reengineering attenuated vaccinia viruses has yielded a deep product pipeline with broad therapeutic and diagnostic applicability. Genelux has demonstrated unparalleled capabilities to produce “customized” viruses for the treatment of specific tumor types by inserting desired genes into its proprietary viral vectors. The company is also unique in developing and integrating diagnostic technologies (optical and deep tissue) into its vaccinia virus-based treatment platforms.
Genelux Corporation is built on a solid foundation of scientific discovery, and holds a strong intellectual property position in the area of oncolytic virology.